Condition Studies
Automated daily PubMed feeds of peer-reviewed research, organized by condition.
- Long COVID →
- PACVS →
- ME/CFS →
- POTS / Dysautonomia →
- MCAS →
- Gulf War Illness →
- Lyme / PTLDS →
- Other Post-Viral (Post-infectious cough, Q-fever fatigue syndrome, Post-dengue fatigue, Chikungunya post-infectious HLH, Parvovirus B19 GBS, Mycoplasma pneumoniae neurological, post-HSV encephalitis, RIME, etc.) →
Post-Viral Illness
Curated, reference-backed treatment options for Long COVID, post-viral ME/CFS, post-dengue, post-polio, chikungunya, post-Ebola, post-infectious POTS, PANS/PANDAS, and post-Zika GBS.
PAIS Cohorts
Design-verified catalogue of post-acute infection syndrome cohorts (not patients): denominator, controls, timepoints, and banked specimens made machine-readable, with gap matrices exposing where no adequate study exists.
Interventional Studies
Actively recruiting and recently completed clinical trials for PACVS, Long COVID, ME/CFS, and related conditions.
Aggregated Evidence
Cross-condition synthesis of therapeutic agents being studied, with evidence levels and linked trial data.
Alterations, Drugs & Natural Products
98-condition database (100-disease cure-vs-chronic list) of biomarkers, ranked therapeutics, natural products, and clinical trial evidence from Open Targets, HPO, ChEMBL, DGIdb, and OSMF reviews.
Medical Freedom Maps
Static, search-indexable HTML — no Vercel/Render app required. Compare procedure access pathways across jurisdictions and healthcare laws across all 50 US states (right to try, scope of practice, telehealth, regenerative medicine, and more).
Condition-Specific Biomarkers
Peer-reviewed biomarker databases for Long COVID, PACVS, ME/CFS, Lyme disease, and Gulf War Illness. Searchable blood test alterations, cytokine panels, metabolites, and CSF markers with DOI citations.
Candidate Therapeutic Agents
Evidence-based review of investigational therapeutic agents for Long COVID, PACVS, ME/CFS, POTS, and MCAS. Filterable by condition, mechanism, and evidence tier with clinical trial data and mechanistic rationale.
PeptideOS
Disinterested evidence on therapeutic peptides: efficacy tiers, regulatory status, purity data. Class A (approved) through Class C (gray market). No dosing advice, no vendors, funded by grants only.
NTD Intelligence
The 21 WHO neglected tropical disease groups — burden, top therapeutic hits, and documented post-infectious syndromes with literature persistence rates (dengue, chikungunya, Chagas, leishmaniasis, and more).